Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice

Study Identifier
P13-682
CT.gov Identifier
NCT01754727
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Axial Spondyloarthritis (axSpA)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Had ankylosing spondylitis (AS) and was eligible to start and/or continue adalimumab therapy according to the local product label and prescription guidelines, * Had been started on adalimumab therapy no more than one (1) month prior to the study enrollment * Had negative result of tuberculosis (TB) screening test or was receiving tuberculosis prophylaxis as per local guidelines * Provided written Authorization to the investigator to use and/or disclose personal and/or health data, or Informed Consent if requested by the Local Regulations
    Exclusion Criteria:
    \- Had contraindications for the treatment with adalimumab

    Protocol Summary

    The purpose of this study was to assess the proportion of AS patients achieving treatment response to adalimumab therapy.

    Study Locations

    No locations found.